Enhancing Primaquine Adherence for Plasmodium vivax Malaria: A Cluster-Randomized Controlled Trial in Myanmar
The American Journal of Tropical Medicine and Hygiene · 2025
DOI: 10.4269/ajtmh.24-0814 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2025. Verfasst von Kyawt Mon Win und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Vivax, Medication Adherence, Primaquine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
The rising prevalence of Plasmodium vivax ( P. vivax ) malaria challenges elimination efforts, particularly in the Greater Mekong Subregion, although adherence to the required 14-day primaquine (PQ) regimen remains a major obstacle. This study evaluated the effectiveness of a family-administered, directly observed treatment intervention in improving adherence to PQ among patients with confirmed P. vivax from October 2022 to March 2023. A cluster-randomized controlled trial was conducted in five intervention villages and five control villages in Kachin State, Myanmar. A total of 427 patients in the intervention group (supervised dosing) and 425 patients in the control group (unsupervised dosing), all diagnosed with P. vivax , underwent a 14-day PQ regimen, with the intervention group being supervised by trained family members. Pill counts on day 14 were assessed and compared between the two groups using Poisson generalized linear mixed models. Parasite reappearance identified by polymerase chain reaction was compared between the two groups using survival analysis. Cumulative malaria incidence at baseline, as well as at months 6 and 12, was compared between the two groups. Treatment adherence was significantly higher in the intervention group (98.8%) compared with the control group (77.6%). Parasite reappearance rates were similar between the groups ( P = 0.20) on days 14, 28, and 42. However, the cumulative incidence of malaria over 1 year was significantly lower in the intervention group ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
- Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
- Department of Public Health, Ministry of Health, Naypyidaw, Myanmar.
- State Public Health Department, Kachin, Myanmar.
- Myanmar Health Network Organization, Yangon, Myanmar.
- Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; and.
Förderung
- NIAID NIH HHS
Zitieren
APA
Win, K. M., Aung, P. L., Linn, N. Y. Y., Ring, Z., Kyaw, M. P., Nguitragool, W., Cui, L., Sattabongkot, J., & Lawpoolsri, S. (2025). Enhancing Primaquine Adherence for Plasmodium vivax Malaria: A Cluster-Randomized Controlled Trial in Myanmar. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.24-0814
Vancouver
Win KM, Aung PL, Linn NYY, Ring Z, Kyaw MP, Nguitragool W, et al. Enhancing Primaquine Adherence for Plasmodium vivax Malaria: A Cluster-Randomized Controlled Trial in Myanmar. The American Journal of Tropical Medicine and Hygiene. 2025. doi:10.4269/ajtmh.24-0814
BibTeX
@article{Win2025,
author = {Win, Kyawt Mon and Aung, Pyae Linn and Linn, Nay Yi Yi and Ring, Zau and Kyaw, Myat Phone and Nguitragool, Wang and Cui, Liwang and Sattabongkot, Jetsumon and Lawpoolsri, Saranath},
title = {Enhancing Primaquine Adherence for Plasmodium vivax Malaria: A Cluster-Randomized Controlled Trial in Myanmar},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2025},
doi = {10.4269/ajtmh.24-0814}
}
EUVIMED